For Health Care Professionals Treating Carcinoid Syndrome

Proven History Of Somatostatin Receptor-Targeted Inhibition1,2

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) targets somatostatin receptors

Somatostatin Receptor-Targeted Inhibition

38%-50 %

Somatostatin Receptor-Targeted Inhibition

30%-48%; n=92

Somatostatin Receptor-Targeted Inhibition

70%-90%; n=92

Learn More
 

†Patients with carcinoid tumors may experience symptom flare-ups while being maintained on Sandostatin® Immediate-release Injection or Sandostatin® LAR Depot. They may be given supplemental Sandostatin Immediate-release Injection for a few days until symptoms are again controlled.1

For Health Care Professionals Treating Carcinoid Syndrome

Preparation And Administration Of Sandostatin® LAR Depot (octreotide acetate for injectable suspension)

Start Video

Successful preparation and administration of Sandostatin® LAR Depot relies on proper suspension technique. Watch a short video on how to properly prepare Sandostatin® LAR Depot.

Watch Video
 

For Health Care Professionals Treating Carcinoid Syndrome

#1 Prescribed Somatostatin Analogue In The World*4

Over 20 years of evidence, and counting1,5,6.

Clinical evidence is supported by:

  • Over 800,000 patient-years of experience*5
Learn More about Sandostatin

*Includes Sandostatin® Immediate-release Injection and Sandostatin® LAR Depot for all approved indications.

Highlights of Important Safety Information

Gallbladder abnormalities may occur: Patients should be monitored periodically.

Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot
treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly.

Please see below for Important Safety Information.

 
 

INDICATIONS AND USAGE:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions:

  • Gallbladder abnormalities may occur: Patients should be monitored periodically.
  • Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly.
  • Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended.
  • Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other EKG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients.
  • Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels.

Drug Interactions: The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution.

Adverse Reactions: The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot are:

  • Acromegaly: biliary abnormalities (52%), diarrhea (36-48%), cholelithiasis (13-38%), abdominal pain or discomfort (11-29%), flatulence (26%), influenza-like symptoms (20%), constipation (19%), headache (15%), anemia (15%), hyperglycemia (15%), injection site pain (2-14%), hypertension (13%), dizziness (12%), fatigue (11%), nausea (10%), vomiting (7%), hypothyroidism (2%), hypoglycemia (2%), and goiter (2%).
  • Carcinoid Tumors and VIPomas: biliary abnormalities (62%), injection site pain (20-50%), nausea (24-41%), abdominal pain (10-35%), fatigue (8-32%), headache (16-30%), hyperglycemia (27%), back pain (8-27%), constipation or vomiting (15-21%), dizziness (18-20%), sinus bradycardia (19%), pruritus (18%), URTI (10-18%), myalgia (4-18%), flatulence (9-16%), arthropathy (8-15%), rash (15%), generalized pain (4-15%), sinusitis (5-12%), conduction abnormalities (9%), hypoglycemia (4%), and arrhythmia (3%).

Please see full Prescribing Information

References

  1. Sandostatin® LAR Depot [prescribing information.]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2011.
  2. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17;1733-1742.
  3. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinioid syndrome. J Clin Oncol. 1999;17;600-606.
  4. IMS Report to Novartis Pharmaceuticals Corp;2010.
  5. Data on file, Novartis Pharmaceuticals Corp.
  6. PubMed [database online]. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/pubmed?term=octreotide Accessed February 2, 2012.